The 2022 AHA/ACC/HFSA Guidelines – Adopting SGLT-2 Inhibitors Across the Spectrum of Heart Failure Quad Therapy in HFrEF: Individualized Approaches to Initiation and Sequencing
The 2022 AHA/ACC/HFSA Guidelines – Adopting SGLT-2 Inhibitors Across the Spectrum of Heart Failure Quad Therapy in HFrEF: Individualized Approaches to Initiation and Sequencing is organized by Projects In Knowledge Inc. (PIK).
Release Date: Mar 24, 2023
Termination Date: Mar 23, 2024
Activity Goal:
The goal of this program is to provide the most current clinical information and practical management strategies of treating heart failure, as seen in clinical practice, in a customized, interactive, and easily digestible on-demand educational program.
Learning Objective(s):
• Formulate optimal treatment strategies for simultaneous or rapid sequence initiation of quadruple therapy for patients with heart failure with reduced ejection fraction.
Additional details will be posted as soon as information is available.